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Despite tremendous efforts in early diagnosis and therapy, the
prognosis for patients with pancreatic carcinoma remains dismal
(Warshaw and Fernandez-del Castillo, 1992; Niederhuber et al,
1995). In advanced pancreatic cancer, drug resistance is a major
obstacle to chemotherapy (Arbuck, 1990; Lionetto et al, 1995;
Schnall and Macdonald, 1996). Considerable evidence shows that
apoptosis plays a key role in tumour cell death induced by several
chemotherapeutic agents (Kerr et al, 1994; Huschtscha et al,
1996). Tumour cells may express defects in the apoptotic pathway
and become resistant to chemotherapy (Thompson, 1995;
Hickman, 1996; Reed et al, 1996). A better understanding of the
mechanisms underlying the resistance to drug-mediated apoptosis
may enhance our ability to treat pancreatic cancer successfully.
Telomerase, a ribonucleoprotein enzyme, elongates and main-
tains telomeric DNA through the addition of TTAGGG repeats and
plays a critical role in the development of cellular immortality and
carcinogenesis (Morin, 1989; Harley et al, 1994; Kim et al, 1994;
Shay and Bacchetti, 1997). We previously reported highly
elevated telomerase activity in 80% of specimens from surgically
resected lesions of pancreatic carcinoma and in 75% of pancreatic
juice samples obtained from patients with ductal carcinoma
(Suehara et al, 1997a, 1997b). Three major components of human
telomerase have been identified: human telomerase RNA, hTERC
(Feng et al, 1995); telomerase-associated protein, TEP1
(Harrington et al, 1997; Nakayama et al, 1997); and human telo-
merase reverse transcriptase, hTERT (Meyerson et al, 1997;
Nakamura et al, 1997). Among these components, hTERT has
been considered a catalytic subunit of telomerase and a rate-
limiting determinant of the enzymatic activity (Bodnar et al, 1998;
Vaziri and Benchimol, 1998).
Although telomerase may be implicated in the cellular response
to apoptosis, the relation between telomerase and vulnerability to
apoptosis remains poorly understood. Antisense inhibition of
telomerase increases the susceptibility of glioblastoma cells to
cisplatin-induced apoptosis (Kondo et al, 1998). Similarly, telom-
erase inhibition with the oligodeoxynucleotide enhances apoptosis
in pheochromocytoma cells induced by a variety of stimuli (Fu et
al, 1999). Enhanced expression of telomerase and maintenance of
telomere stability increase cellular resistance to apoptosis trig-
gered by serum starvation or matrix deprivation (Holt et al, 1999).
These findings suggest a protective role of telomerase against
apoptotic cell death. We hypothesized that telomerase activity
could be one determinant of vulnerability to drug-induced apop-
tosis. Studies on telomerase regulation in cancer cells treated with
antineoplastic agents could elucidate the functional role of this
enzyme in drug-induced apoptosis.
In the present study, we investigated the dynamics of telomerase
activity in human pancreatic cancer cells treated with etoposide,
which is known to cause DNA strand breaks and to induce apop-
tosis in diverse cell types (Barry et al, 1993; Mizumoto et al, 1994;
Okamoto-Kubo et al, 1994; Bonelli et al, 1996; Lock and
Stribinskiene, 1996; Hande, 1998). We found increased telomerase
activity after etoposide exposure in cell lines that showed resis-
tance to etoposide-induced apoptosis. To the best of our knowl-
edge, this is the first report describing up-regulation of telomerase
activity in response to etoposide. Our results support the hypoth-
esis that telomerase plays a protective role against DNA damage
and subsequent apoptosis through its up-regulation pathway.
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Summary Telomerase plays a critical role in the development of cellular immortality and oncogenesis. Activation of telomerase occurs in a
majority of human malignant tumours, and the relation between telomerase and vulnerability to drug-mediated apoptosis remains unclear. In
this study, we demonstrate, for the first time, up-regulation of telomerase activity in human pancreatic cancer cells treated with etoposide, a
topoisomerase II inhibitor. Exposure of MIA PaCa-2 cells to etoposide at various concentrations (1–30 mM) resulted in two- to threefold
increases in telomerase activity. Up-regulation was detectable 24 h after drug exposure and was accompanied by enhanced expression of
mRNA of the human telomerase reverse transcriptase. Telomerase activation was also observed in AsPC-1 and PANC-1 cells but not in
KP-3 and KP-1N cells. Furthermore, we found a negative correlation between increased telomerase activity and the percentage of dead cells
after etoposide treatment. These findings suggest the existence of an anti-apoptotic pathway through which telomerase is up-regulated in
response to DNA damage. This telomerase activation pathway may be one of the mechanisms responsible for the development of etoposide
resistance in certain pancreatic cancer cells. © 2000 Cancer Research Campaign
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Cell lines and culture conditions
Five human pancreatic cancer cell lines were used in this study:
MIA PaCa-2 was provided by the Japanese Cancer Resource Bank
(Tokyo, Japan); AsPC-1, PANC-1, KP-3, and KP-1N were
donated by Dr Iguchi (National Kyushu Cancer Center, Fukuoka,
Japan). Cells were maintained in Dulbecco’s modified Eagle’s
medium (Sigma Chemical Co., St Louis, MO, USA) supplemented
with 10% fetal bovine serum, streptomycin (100 mg ml–1), and
penicillin (100 U ml–1) at 37°C in a humidified atmosphere
containing 10% carbon dioxide.
Drug treatment
Etoposide (Nippon Kayaku Co., Ltd., Tokyo, Japan) was dissolved
in dimethylsulphoxide (DMSO) at 10 mM as a stock solution.
Cells in log phase growth were seeded at a density of 5 ´ 104 cells
well–1 in 12- or 24-well plates. After overnight incubation, the
cells were exposed continuously to etoposide at various concentra-
tions. Cell number and mean cell diameter were measured with a
particle distribution analyser, CDA500 (Sysmex, Kobe, Japan).
Five days after the beginning of treatment, cell viability was
assessed with the cell-death assay described below.
Measurement of DNA synthesis
DNA synthesis was determined with the [3H]thymidine incorpora-
tion test. Cells were exposed to etoposide (5 mM) for 24 h and
pulsed for 4 h with 1 mCi ml–1 of [3H]thymidine. The incorporation
of [3H]thymidine into trichloroacetic acid-insoluble material was
measured with a liquid scintillation counter.
Cell cycle analysis
Cells were harvested at indicated time points, washed twice in
phosphate-buffered saline (PBS) and fixed with cold 70% ethanol
for 4 h at 4°C. Fixed cells were then washed with PBS, incubated
with RNAase (100 mg ml–1) for 30 min at room temperature,
stained with propidium iodide (PI, Sigma, 50 mg ml–1) and
analysed on a FACScan flow cytometer (Becton Dickinson,
Bedford, MA, USA).
Assessment of apoptosis
After drug treatment, detached cells were combined with mono-
layer cells that had been detached by trypsinization and applied to
glass slides with cytospin preparations. Cells were fixed in cold
methanol, and membranes were permeabilized with 0.2% Triton
X-100 (Sigma) and stained with DNA dye, PI. Nuclear
morphology was observed under a laser-scanning microscope,
Olympus LSM-GB200 system (Tokyo, Japan).
Quantitative measurement of dead cells
Dead cells were measured quantitatively with a multiwell fluores-
cence scanner by the method described previously (Sato et al,
1998). This method is based on the binding of PI to the nuclei of
cells with plasma membranes that are permeable as a result of cell
death. The percentage of dead cells was defined as the proportion
of fluorescence intensity corresponding to dead cells to that of
total cells.
Telomerase activity assay
Telomerase activity was measured based on a telomerase repeat
amplification protocol (TRAP) assay (Kim et al, 1994) performed
with a TRAPeze Telomerase Detection Kit (Intergen, Purchase,
NY, USA) according to the manufacturer’s instructions. For a
sensitive and semiquantitative telomerase assay, cell extracts were
diluted to a concentration equivalent to a constant number of cells
for each assay. PCR products were resolved by electrophoresis on
a 12% polyacrylamide gel and visualized with SYBR Green DNA
stain (FMC Bioproducts, Rockland, ME, USA). A 36-bp internal
standard was used as an internal control. For quantification of
telomerase activity in each sample, the total density of the entire
ladder was measured with NIH-Image software (NTIS,
Springfield, VA, USA).
RT-PCR analysis
Analysis of the mRNA expression of hTERT, TEP1 and hTERC
was performed by reverse transcription polymerase chain reaction
(RT-PCR) amplification. An Isogen RNA extraction kit (Nippon
Gene, Tokyo, Japan) was used to isolate total RNA from the cell
pellets. cDNA was synthesized from 2 mg of RNA with the RNA
PCR kit (Takara Shuzo Co. Ltd, Otsu, Japan) and random primers.
Two-microlitre aliquots of the reverse-transcribed cDNA were
subjected to PCR amplification with an initial incubation step at
94°C for 3 min, followed by 33 cycles at 94°C for 45 s, 60°C for
45 s and 72°C for 90 s. The primer pairs were as follows: 5¢-
TGAGTGTGTACGTCGTCGAG-3¢ (sense) and 5¢-GAACG-
TTCTGGCTCCCACGA-3¢ (antisense) for hTERT; 5¢-TCA-
AGCCAAACCTGAATCTGAG-3¢ (sense) and 5¢-CCCCGAGT-
GAATCTTTCTACGC-3¢ (antisense) for TEP1; and 5¢-TCTAAC-
CCTAACTGAGAAGGGCGTAG-3¢ (sense) and 5¢-GTTTGCT-
CTAGAATCAACGGTGGAAG-3¢ (antisense) for hTERC. The
PCR products were separated on a 2% agarose gel and visualized
by ethidium bromide staining.
Statistical analysis
The results of parametric data are expressed as means ± standard
deviation (s.d.). Correlation between the magnitude of telomerase
up-regulation and the percentage of dead cells was assessed with
the Spearman’s rank correlation test. P < 0.05 was considered
significant.
RESULTS
Cytotoxic effect of etoposide on MIA PaCa-2 cells
We first evaluated the cytotoxicity of etoposide on MIA PaCa-2
cells. Control cells were treated with solvent (DMSO) alone.
Treatment with etoposide (5 mM) completely inhibited the growth
of MIA PaCa-2 cells (Figure 1A). DNA synthesis, determined by
the [3H]thymidine incorporation test, decreased after etoposide
exposure. The [3H]thymidine uptake in cells treated with 5 mM
etoposide for 24 h was 41.8 ± 0.3% that of control cells. Flow
cytometric analysis revealed that the cells were arrested at the
G2/M phase 48 h after etoposide treatment. In control cells, the
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In cells treated with etoposide for 48 h, the values were 21% for
G0/G1, 22% for S, and 57% for G2/M. Morphologically, cells
exposed to etoposide were enlarged with a mean cell diameter of
24.7 ± 3.7 mm 24 h after treatment compared to 21.3 ± 3.0 mm in
control cells (Figure 1B). Apoptotic cell death, characterized by
cell shrinkage, plasma membrane blebbing, chromatin condensa-
tion and nuclear fragmentation, was detectable in a small number
of cells beginning on day 3 (Figure 1C). The percentage of dead
cells in the culture treated with 5 mM etoposide was 7.7 ± 1.2% on
day 5. Almost no cell death was observed in solvent-treated cells
(data not shown).
Up-regulation of telomerase activity in MIA PaCa-2 cells
treated with etoposide
To determine an appropriate concentration (cell number equiva-
lent) of cell extract that would permit reliable quantification of
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Figure 1 Cytotoxic effect of etoposide on MIA PaCa-2 cells. (A) Growth kinetics of MIA PaCa-2 cells treated with solvent alone (closed square) or 5 mM
etoposide (closed circle). Cell numbers are means ± s.d. of three independent wells. (B) Phase contrast photomicrographs of MIA PaCa-2 cells exposed to
solvent (left panel) or 5 mM etoposide (right panel) for 48 h; ´100. (C) Nuclear morphology of MIA PaCa-2 cells 72 h after treatment with solvent (left panel) or 
5 mM etoposide (right panel) stained with propidium iodide. Apoptotic cells manifesting nuclear fragmentation are observed in a small fraction of etoposide-
treated cells (arrow). Bars, 20 mmrelative levels of telomerase activity, the basal level of telomerase
activity was measured in a serial dilution of the MIA PaCa-2 cell
extract. One hundred to 3000 cell equivalents were within linear
range of the relative telomerase activity (Figure 2A). In subse-
quent assays, we applied extracts equivalent to 102 cells to
precisely detect differences in telomerase activity. Twenty-four
hours after treatment with etoposide at various (0.1–30 mM)
concentrations, we examined MIA PaCa-2 cells for changes in
telomerase activity. Etoposide significantly enhanced telomerase
activity of treated cells even at relatively low doses (Figure 2B).
The maximum telomerase up-regulation was obtained at a concen-
tration of 5 mM. A time course experiment of telomerase activity in
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Figure 2 Up-regulation of telomerase activity in MIA PaCa-2 cells treated with etoposide. (A) Telomerase activity in serial dilution of cellular extracts,
corresponding to 10 (lane 1), 30 (lane 2), 100 (lane 3), 300 (lane 4), 1000 (lane 5), 3000 (lane 6) and 10 000 (lane 7) cells. Data points, relative density unit of
telomerase ladders in each lane. Linearity of the ladder density was observed between 100 and 3000 cell equivalents. (B) Telomerase activity in cells treated for
24 h with etoposide at a concentration of 0 (control, lane 1), 0.1 (lane 2), 1 (lane 3), 5 (lane 4), 10 (lane 5) and 30 mM (lane 6). Columns, relative density of
telomerase ladders to that of control cells. (C) Telomerase activity in cells treated with etoposide for 0 (control, lane 1), 6 (lane 2), 12 (lane 3), 24 (lane 4), 48
(lane 5), 72 (lane 6) and 96 h (lane 7) at a concentration of 5 mM. Data points, relative density of telomerase ladders to that of control cellsMIA PaCa-2 cells treated with 5 mM etoposide revealed elevated
levels as early as 24 h after treatment began and increases up to
approximately threefold the control level at 48 h (Figure 2C).
After 72 h, telomerase activity decreased gradually and returned to
the pretreatment level at 96 h. When etoposide was added directly
to MIA PaCa-2 cell extracts immediately before primer addition,
telomerase activity remained unchanged (data not shown). Thus, a
direct influence of etoposide on TRAP assay does not seem to be
involved in the telomerase activation observed after drug treat-
ment.
Effect of etoposide on mRNA expression of hTERT,
TEP1 and hTERC in MIA PaCa-2 cells
We also examined the effect of etoposide on the mRNA expres-
sions of three telomerase subunits, hTERT, TEP1 and hTERC 
by RT-PCR. MIA PaCa-2 cells treated with etoposide (5 mM)
displayed a substantial increase in hTERT mRNA expression
(Figure 3). The increased level was detectable at 24 h, peaked at 
48 h after drug exposure, and paralleled the up-regulation of
telomerase activity encountered in the treated cells. In contrast, no
significant increase was observed in TEP1 and hTERC mRNA
levels during etoposide treatment. These results suggest that
hTERT plays a critical role in the regulation of telomerase activity
and that etoposide up-regulates telomerase activity of treated cells
through induction of hTERT mRNA expression.
Relation between telomerase up-regulation and
sensitivity to etoposide-induced cell death
Other cell lines were treated with etoposide at a concentration of 
5 mM and assayed for telomerase activity in the same manner.
AsPC-1 and PANC-1 cells exhibited an increase in telomerase
activity, whereas KP-3 and KP-1N cells showed no significant
change after etoposide treatment (Figure 4 and Table 1). Since
telomerase is implicated in the anti-apoptotic phenotypes, we
attempted to determine whether a correlation exists between
telomerase activity and etoposide-induced apoptosis. MIA PaCa-
2, AsPC-1 and PANC-1, all of which showed telomerase elevation,
Etoposide up-regulates telomerase activity 1823
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Figure 3 RT-PCR analysis of mRNA expression of hTERT, TEP1, hTERC
and b-actin (as a control) in MIA PaCa-2 cells treated with etoposide for 0, 6,
12, 24 and 48 h at a concentration of 5 mM. A marked increase is apparent in
the mRNA expression of hTERT, whereas no significant change is detectable
in those of TEP1 and hTERC
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Figure 4 Effect of etoposide on telomerase activity in four pancreatic
cancer cell lines. Cells were treated with etoposide (5 mM) for 24 h and 48 h,
and telomerase activity was assessed. Telomerase up-regulation is shown in
AsPC-1 and PANC-1 cells but not in KP-3 and KP-1N cells
Table 1 The magnitude of telomerase up-regulation and cell death in
pancreatic cancer cell lines treated with etoposide
Fold increase in telomerase Percentage dead cells 
Cell line activitya (mean ± s.d.)b 
MIA PaCa-2 2.9 7.7 ± 1.2%
AsPC-1 3.1 2.5 ± 0.8%
PANC-1 2.2 21.8 ± 2.7%
KP-3 1.3 37.5 ± 5.4%
KP-1N 1.1 54.5 ± 0.8%
aRatio of the highest telomerase activity in cells treated with etoposide (5 mM)
to that of control cells. bPercentage of dead cells 5 days after treatment with
etoposide (5 mM).were relatively resistant to etoposide-mediated apoptosis. The
percentage of dead cells at day 5 was 7.7 ± 1.2% in MIA PaCa-2,
2.5 ± 0.8% in AsPC-1, and 21.8 ± 2.7% in PANC-1 (Table 1). KP-
3 and KP-1N, with unchanged telomerase activity, were sensitive
to etoposide-induced lethality. The proportion of dead cells was
37.5 ± 5.4% in KP-3 and 54.5 ± 0.8% in KP-1N. The magnitudes
of telomerase up-regulation (the ratio of the highest telomerase
activity to that of control cells) in these five lines were signifi-
cantly correlated with the percentages of dead cells (P < 0.05;
Figure 5). These findings indicate that some types of pancreatic
cancer cells may escape etoposide-induced apoptotic crisis via the
mechanism of telomerase activation.
DISCUSSION
The aim of this study was to investigate the effect of etoposide on
telomerase activity and to clarify the relation between telomerase
dynamics and etoposide-mediated apoptotic cell death. The results
demonstrate that etoposide enhances telomerase activity in human
pancreatic cancer cells by including its catalytic subunit hTERT
mRNA expression. Our findings have implications for under-
standing the potential role of telomerase in cancer cells.
Our present data conflict with previous studies that found no
significant change in telomerase activity in leukaemic cells and
nasopharyngeal carcinoma cells after etoposide treatment (Ku et
al, 1997; Akiyama et al, 1999). Direct comparison of these studies
and ours is difficult because of differences in cell lines used and in
methodologies. Telomerase plays an essential role in the mainte-
nance of genomic integrity (Lee et al, 1998), and its activation
upon exposure to etoposide could result from the need of cells to
repair DNA. This idea is supported by a study describing the stabi-
lization of broken chromosomes by the direct addition of telomeric
repeats to nontelomeric DNA (Flint et al, 1994). Healing process
of broken DNA might be mediated by telomerase. Consistent with
our present results, a previous report showed up-regulation of
telomerase activity in haematopoietic cells after exposure to
ionizing radiation (Leteurtre et al, 1997).
Factors suggested to influence telomerase activity include
cellular proliferation, cell cycle progression, differentiation,
cellular senescence and apoptosis. Telomerase activity is associ-
ated with cell proliferation (Belair et al, 1997). However, our data
show that etoposide inhibits the growth and DNA synthesis of
treated cells rather than promotes their proliferation. The relation
between telomerase activity and cell cycle is controversial (Holt et
al, 1997). During cell cycle progression, telomerase activity has
been noted as highly activated in the S phase and barely detectable
in the G2/M phase (Zhu et al, 1996). We found that etoposide
arrested most cells at the G2/M phase of the cell cycle by 48 h
after treatment, when the telomerase up-regulation was maximal.
Telomerase elevation in response to etoposide may not be related
to the cell cycle-dependent modulation of this enzyme. Telomerase
activity is also modulated by apoptosis. When tumour cell lines
were treated with antineoplastic agents, including cisplatin and
adriamycin, drug-induced cell killing was associated with a
decline in telomerase activity (Faraoni et al, 1997). Apoptotic cells
with an intact plasma membrane were reported to maintain high
telomerase activity, whereas cells with plasma membrane damage
lost telomerase activity (Akiyama et al, 1999). In our present
study, telomerase elevation was detectable as early as 24 h after
etoposide exposure, prior to the appearance of apoptotic cell death.
After 72 h, telomerase activity slowly decreased, which is consis-
tent with the loss of enzymatic activity resulting from apoptotic
cell death. Etoposide-mediated telomerase activation may be a
relatively early event that is independent of cell proliferation, cell
cycle and apoptotic cell death.
We also examined the linkage between telomerase activity and
vulnerability to etoposide-induced apoptosis. Although some
investigators have suggested an anti-apoptotic role of telomerase
in different cell types, the functional role of this enzyme in the
drug-induced apoptosis remains poorly understood. We did not
observe a significant relation between the basal level of telomerase
activity in individual lines and their susceptibilities to etoposide-
induced apoptosis (results not shown). We did find a negative
correlation between increased telomerase activity and the
percentage of dead cells after etoposide treatment. These findings
raise the possibility that the elevated activity of telomerase can
confer a survival advantage upon tumour cells and contribute to
their decreased sensitivity to etoposide-mediated apoptosis.
Detection of telomerase elevation, rather than the basal level of the
enzyme, could be efficacious in determining the potential success
of chemotherapy.
Susceptibility to drug-induced apoptosis is modulated by
various genetic and biochemical alterations. For example, p53
tumour suppressor gene product is essential for proper induction
of apoptosis (Lowe et al, 1993, 1994). Tumour cells harbouring
mutant p53 are generally more resistant to DNA damaging agents,
such as etoposide, than cell expressing wild-type p53 (Fan et al,
1994; Perego et al, 1996; O’Connor et al, 1997). Regarding the
p53 gene status, all the lines used in this study have p53 mutations
except for KP-3 (Iguchi et al, 1994). Thus, p53 alone can not
explain the different responses to etoposide-induced cell killing
between these cell lines. Several complex factors, such as other
genes controlling apoptosis, may be involved in the mechanisms
underlying drug resistance of cancer cells. Our present results
suggest that telomerase activation might be one of the key events
responsible for the development of drug resistance in certain
tumour cell types.
In conclusion, we observed increased telomerase activity after
etoposide exposure. Although further studies will be required to
delineate the precise mechanism by which telomerase activity is
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Figure 5 Relation between the magnitude of telomerase up-regulation and
vulnerability to etoposide-induced apoptosis in five pancreatic cancer cell
lines. There is a significant negative correlation between maximum
telomerase activity (ratio to control) upon exposure to etoposide and
percentage of dead cells at day 5 (P < 0.05)up-regulated in response to DNA damage, our data suggest that a
close linkage exists between vulnerability to drug-mediated apop-
tosis and activation of telomerase in human pancreatic cancer
cells. A targeted blockage of this telomerase elevation pathway
could be a potential anticancer strategy for sensitizing tumour cells
to certain antineoplastic agents.
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